Ranibizumab (Lucentis, Genentech, South San Francisco, CA), a humanized monoclonal antibody fragment, was the first anti-VEGF agent shown to improve visual acuity in patients with wet AMD, and it was approved for use in wet AMD in Europe in 2007 [4]. This evidence concerns the gene VEGFA and wet macular degeneration.